logo
logo
logo
logo
  • Our Science
    • Therapeutics
    • Vaccination
  • Our Platform
  • Get To Know Us
  • News & Updates
  • Get In Touch

News & Updates

November 30, 2022

Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial Pneumonia

Read More

October 5, 2022

Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101

Read More

April 4, 2022

CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial Infections

Read More

December 20, 2021

Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial Infections

Read More

November 5, 2021

New Publication in Cell Implicates a Rare Form of DNA Driving Antimicrobial Resistance in Bacterial Biofilms

Read More

September 1, 2021

Clarametyx Biosciences Awarded $2.7 Million in Option Funding From CARB-X to Accelerate Novel Technology for Persistent Bacterial Infections

Read More

May 20, 2021

Clarametyx Biosciences Expands Board of Directors with Appointment of Financial Executive Michael Layman

Read More

March 15, 2021

Clarametyx featured in 2021 Technology Showcase, hosted by Nationwide Children’s Hospital’s Office of Technology Commercialization

Read More

January 5, 2021

David Richards Appointed CEO of Clarametyx Biosciences

Read More

Loading…

Sign-up to get updates from Clarametyx

[contact-form-7 404 "Not Found"]

Our ScienceGet To Know Us

News & UpdatesGet In Touch

Our ScienceGet To Know UsNews & UpdatesGet In Touch


Copyright © 2022 Clarametyx Biosciences. All rights reserved. Privacy Policy.